The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

An announcement from Ionis Pharmaceuticals ( ($IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares ...

Daughter Of Billionaire Hedge Fund Founder Donates $250,000 To Socialist NYC Mayoral candidate Mamdani Super PAC (The Post ...